U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H33O5.Na
Molecular Weight 424.5056
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEHYDROCHOLATE SODIUM

SMILES

[Na+].[H][C@@]1(CC[C@@]2([H])[C@]3([H])C(=O)C[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC(=O)[C@]12C)[C@H](C)CCC([O-])=O

InChI

InChIKey=FKJIJBSJQSMPTI-CAOXKPNISA-M
InChI=1S/C24H34O5.Na/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26;/h13-14,16-18,22H,4-12H2,1-3H3,(H,28,29);/q;+1/p-1/t13-,14+,16-,17+,18+,22+,23+,24-;/m1./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C24H33O5
Molecular Weight 401.5158
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/5935948

Dehydrocholic acid is manufactured from cholic acid by oxidation. The main use of dehydrocholic acid is as a digestive aid in the dietary supplement industry. It is typically formulated with enzymes like papain and pancreatin. It has a stimulating effect on the secretion of bile by the liver (choleretic); improves absorption of essential food materials in states associated with deficient bile formation.

CNS Activity

Curator's Comment: In rats, sodium dehydrocholate disrupts the blood-brain barrier for a period of over 3 days.

Originator

Curator's Comment: Hammarsten in 1881 succeeded in converting cholic acid into dehydrocholic acid

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Anionic polypeptide fraction (APF) secretion in bile
Target ID: Q99626
Gene ID: 1045.0
Gene Symbol: CDX2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Decholinum

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
250 mg 3 times / day multiple, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 36-75
n = 11
Health Status: unhealthy
Condition: recurrent acute cholangitis
Age Group: 36-75
Sex: M+F
Population Size: 11
Sources:
Other AEs: Nausea, Diarrhea...
Other AEs:
Nausea (1 patient)
Diarrhea (1 patient)
Weight loss (1 patient)
Pain in hand (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea 1 patient
250 mg 3 times / day multiple, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 36-75
n = 11
Health Status: unhealthy
Condition: recurrent acute cholangitis
Age Group: 36-75
Sex: M+F
Population Size: 11
Sources:
Nausea 1 patient
250 mg 3 times / day multiple, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 36-75
n = 11
Health Status: unhealthy
Condition: recurrent acute cholangitis
Age Group: 36-75
Sex: M+F
Population Size: 11
Sources:
Pain in hand 1 patient
250 mg 3 times / day multiple, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 36-75
n = 11
Health Status: unhealthy
Condition: recurrent acute cholangitis
Age Group: 36-75
Sex: M+F
Population Size: 11
Sources:
Weight loss 1 patient
250 mg 3 times / day multiple, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: multiple
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 36-75
n = 11
Health Status: unhealthy
Condition: recurrent acute cholangitis
Age Group: 36-75
Sex: M+F
Population Size: 11
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Influence of dehydrocholate sodium on the biliary reabsorption of sulfobromophtalein sodium from the rat biliary tree after retrograde intrabilary injection.
1976 Aug 15
Effects of sodium ursodeoxycholate, hyodeoxycholate and dehydrocholate on cholesterol and bile acid metabolism in rats.
1983 May
Anodic electrochemical oxidation of cholic acid.
2001 Feb
Choledocholithiasis in an infant of extremely low birthweight.
2002 Apr
Choleretic activity and biliary elimination of lipids and bile acids induced by an artichoke leaf extract in rats.
2002 Dec
Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
2002 Jun 17
Spasmocanulase in irritable bowel syndrome.
2002 Sep
Sterol-derived hormone(s) controls entry into diapause in Caenorhabditis elegans by consecutive activation of DAF-12 and DAF-16.
2004 Oct
Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex.
2004 Sep 8
A novel insulin derivative chemically modified with dehydrocholic acid: synthesis, characterization and biological activity.
2005 Aug
Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium.
2006 Jan
Regio- and stereoselective reductions of dehydrocholic acid.
2006 Jun
Aqueous sodium dehydrocholate-sodium deoxycholate mixtures at low concentration.
2007 Oct 15
Magnetic resonance cholangiopancreatography: potential usefulness of dehydrocholic acid (DHCA) administration in the evaluation of anastomotic site.
2008 Jan-Feb
Study on bioactive compounds of in vitro cultured Calculus Suis and natural Calculus Bovis.
2009 Dec
Thermodynamic and elastic fluctuation analysis of Langmuir mixed monolayers composed by dehydrocholic acid (HDHC) and didodecyldimethylammonium bromide (DDAB).
2010 Jan 1
Patents

Sample Use Guides

In Vivo Use Guide
in rats: intravenously as a constant infusion (3.1 mumol/min/kg body weight) or as a bolus injection (24.8 mumol/rat)
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:01:55 UTC 2023
Edited
by admin
on Fri Dec 15 15:01:55 UTC 2023
Record UNII
W4193719XR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEHYDROCHOLATE SODIUM
Common Name English
Sodium 3,7,12-trioxo-5β-cholan-24-oate
Systematic Name English
DEHYDROCHOLIC ACID SODIUM SALT
MI  
Common Name English
CHOLAN-24-OIC ACID, 3,7,12-TRIOXO-, SODIUM SALT, (5.BETA.)-
Common Name English
SODIUM DEHYDROCHOLATE
INN   WHO-DD  
INN  
Official Name English
sodium dehydrocholate [INN]
Common Name English
DEHYDROCHOLIC ACID SODIUM SALT [MI]
Common Name English
Sodium dehydrocholate [WHO-DD]
Common Name English
DECHOLIN SODIUM
Brand Name English
NSC-756707
Code English
Classification Tree Code System Code
NCI_THESAURUS C66913
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL514446
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
SMS_ID
100000083547
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
NCI_THESAURUS
C76604
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
DRUG BANK
DBSALT001944
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
CAS
145-41-5
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
EVMPD
SUB10556MIG
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
EPA CompTox
DTXSID00883335
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
MERCK INDEX
m4142
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY Merck Index
INN
158
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
NSC
756707
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
FDA UNII
W4193719XR
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
ECHA (EC/EINECS)
205-652-1
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
PUBCHEM
23675007
Created by admin on Fri Dec 15 15:01:55 UTC 2023 , Edited by admin on Fri Dec 15 15:01:55 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE